Now, with a median follow-up of more than 10 years, the long-term results provide important clarity.
Efficacy: Reassuring after 10 years
Non-inferiority of the seven-fraction schedule versus the conventionally fractionated schedule was confirmed for the primary endpoint, failure-free survival. The adjusted hazard ratio was 0.84 (95% CI 0.69–1.03), well below the prespecified critical HR limit set by the 4% non-inferiority margin.
Superiority was not demonstrated (log-rank p=0.12); however, the Kaplan–Meier curves for failure-free survival showed a late separation, suggesting a potential long-term benefit in favour of ultra-hypofractionation. A similar pattern was also observed in the secondary endpoints. At the timepoint 10 years, failure-free survival differed significantly between groups (72% vs 65%; p=0.025). Overall survival at 10 years was 81% with ultra-hypofractionation and 79% with conventional fractionation (log-rank p=0.34).
Taken together, there is no indication of reduced efficacy with the shorter regimen. On the contrary, the consistent direction of effect across endpoints provides reassurance that abbreviated treatment does not come at the expense of tumour control — and may even confer modest benefits. The long-term stability of the efficacy of this ultra-hypofractionated regimen is particularly reassuring.
Toxicity: A Central Question
Perhaps the most important 10-year finding is not only non-inferiority in cancer control, but also equivalence in late toxicity. Notably, the two HYPO-RT-PC schedules were designed to be iso-effective for late normal tissue complications, and the 10-year data closely align with that expectation. No statistically significant between-group differences were observed in the cumulative incidence of late RTOG toxicity at any grade. The 10-year cumulative incidence of late grade ≥2 genitourinary toxicity was 28% in the ultra-hypofractionated group versus 30% in the conventionally fractionated group (HR 1.01, p=0.95). For gastrointestinal toxicity, the incidence was 14% in both groups (HR 0.94, p=0.72). These rates are not negligible; however, they are comparable, and crucially, there is no evidence that the larger fraction sizes used in ultra-hypofractionation per se increase long-term toxicity.
It is important to recall that HYPO-RT-PC was conducted using radiotherapy techniques that would today be considered relatively basic rather than contemporary approaches, such as MRI-only based planning, use of rectal spacers, online imaging, and adaptive workflows.
If equivalence in late toxicity is maintained under those conditions, it strongly suggests that fractionation itself is not the primary driver of late adverse effects. The implication is clear: seven fraction schedule is not intrinsically more toxic than conventional fractionation. Rather, total dose and treatment technique, more than fraction size alone, are likely the dominant determinants of long-term toxicity.
What This Means for Clinical Practice
The debate surrounding ultra-hypofractionation has evolved considerably over the past two decades. Early skepticism has gradually given way to broader acceptance, supported by randomized trial data with shorter follow-up. However, in radiation oncology, long-term follow-up beyond 10 years is uncommon.
The HYPO-RT-PC results now provide mature evidence that the seven-fraction schedule:
- Maintains cancer control
- Does not increase late toxicity
Thus, the remaining challenge is not whether ultra-hypofractionation is safe and effective, but how best to refine and individualize its delivery.
Looking Forward
The field has progressed from questioning the biological plausibility of ultra-hypofractionation to focusing on optimizing its clinical implementation. Future developments are likely to focus on integration with systemic therapies, risk-adapted treatment intensification, advances in imaging, and biologically guided personalized therapy.
With 10 years of follow-up, the HYPO-RT-PC trial establishes seven-fraction ultra-hypofractionation as a mature, evidence-based standard-of-care option for patients with intermediate-risk prostate cancer. The long-term randomized data demonstrate no excess risk of late toxicity associated with this regimen. For both patients and clinicians, this reassurance regarding long-term safety may represent the most meaningful outcome of the trial.
Written by: Per Nilsson1 and Adalsteinn Gunnlaugsson2
- Radiation Physics, Department of Haematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden; Division of Medical Radiation Physics, Department of Clinical Sciences, Lund University, Lund, Sweden.
- Radiation Physics, Department of Haematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden; Division of Oncology, Department of Clinical Sciences, Lund University, Lund, Sweden.